A woman with advanced ovarian cancer has become the first patient in the world to receive a pioneering engineered immune cell therapy. The landmark Phase 1 trial aims to test the treatment's safety and effectiveness against ovarian cancer and other hard-to-treat cancers, offering fresh hope for patients with limited treatment options.